SGLT3: Key Regulator of Sugar Metabolism and Cell Signaling (G6527)

Target Name: SLC5A4

NCBI ID: G6527

SLC5A4

SGLT3: Key Regulator of Sugar Metabolism and Cell Signaling

SLC5A4 (SGLT3) is a gene that encodes a protein known as sialyl-separated membrane protein-5 (SGLT3). The SGLT3 protein is expressed in many different tissues and cells in the body, including the kidneys, intestines, and endothelial cells. It is a key regulator of sugar uptake and utilization, and has been implicated in a number of health conditions, including diabetes, obesity, and cardiovascular disease.

One of the unique features of the SGLT3 protein is its ability to transport sugar across cell membranes. This is accomplished through a process called sialyl transfer, in which the SGLT3 protein transfers a sugar molecule to the cell surface via a sugar transporter. Once the sugar is on the cell surface, it can be consumed by the cell or used to synthesize other molecules.

SGLT3 is also involved in the regulation of water and electrolyte balance. It helps to keep the balance between water and electrolytes in the body by allowing sugar to be absorbed into the bloodstream and then transported to the cells where it can be used for energy or to maintain the integrity of cell membranes.

In addition to its role in sugar metabolism, SGLT3 has also been shown to have a number of potential drug-like properties. For example, it has been shown to be a potent inhibitor of the enzyme PKA, which is involved in the signaling pathway that regulates cell growth and differentiation. This means that SGLT3 may be a good candidate for drugs that are designed to inhibit PKA and prevent cancer, aging, and other diseases.

Another potential application of SGLT3 is as a biomarker for diagnostic purposes. The SGLT3 protein is expressed in many different tissues and cells in the body, and its levels can be measured using techniques such as qRT-PCR or mass spectrometry. This allows researchers to study the expression and function of SGLT3 in a variety of biological samples, including urine, blood, and tissue.

In addition to its potential drug-like properties and as a biomarker, SGLT3 is also a good candidate as a potential target for new therapies. Researchers have developed a number of compounds that are designed to interact with SGLT3 and inhibit its activity. These compounds have has been shown to be effective in a variety of cellular and animal models of disease, including diabetes, obesity, and cardiovascular disease.

Overall, SGLT3 is a protein that has important roles in sugar metabolism and cell signaling. Its potential as a drug target and biomarker make it an attractive target for researchers to investigate further. Further studies are needed to fully understand the function and potential of SGLT3 in the body.

Protein Name: Solute Carrier Family 5 Member 4

Functions: Has electrogenic activity in response to glucose, and may function as a glucose sensor (PubMed:13130073, PubMed:17110502, PubMed:20421923, PubMed:22766068). Mediates influx of sodium ions into the cell but does not transport sugars (PubMed:13130073, PubMed:22766068). Also potently activated by imino sugars such as deoxynojirimycin (DNJ) (PubMed:17110502, PubMed:20421923, PubMed:22766068)

The "SLC5A4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC5A4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets